Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ANPEP | P15144 | 1/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | KLK7 | P49862 | 2/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18879557 | 0.89 | ANPEP (0.52) | MAPTANPEPDPP8DPP7DPP4 | |
| SCHEMBL6046926 | 0.86 | SYK (0.54) | MAPTSYKL3MBTL1MAPK1 | |
| SCHEMBL2584350 | 0.85 | KLK7 (0.50) | MAPTKLK7KLK5 | |
| SCHEMBL30678146 | 0.84 | MAPT (0.49) | MAPTANPEPDPP8DPP7DPP4 | |
| SCHEMBL30678048 | 0.84 | MAPT (0.49) | MAPTANPEPDPP8DPP7DPP4 | |
| SCHEMBL5490556 | 0.84 | MAPT (0.59) | MAPTANPEPDPP8DPP7DPP4 | |
| SCHEMBL7979181 | 0.84 | MAPT (0.59) | MAPTANPEPDPP8DPP7DPP4 | |
| SCHEMBL20168169 | 0.84 | MAPT (0.59) | MAPTANPEPDPP8DPP7DPP4 | |
| SCHEMBL4142816 | 0.84 | SYK (0.52) | MAPTSYKL3MBTL1POLBMAPK1 | |
| SCHEMBL24235717 | 0.83 | MEN1 (0.52) | MAPTANPEPDPP8DPP7KLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2349241-B1 | PHARMACEUTICAL COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS | SIGNATURE THERAPEUTICS INC (US) | 2019-06-19 | — | — | EP | disclosed |
| US-9585963-B2 | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9534014-B2 | Pharmaceutical compositions with attenuated release of phenolic opioids | SIGNATURE THERAPEUTICS, INC. (US) | 2017-01-03 | — | — | US | disclosed |
| US-9238020-B2 | Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug | SIGNATURE THERAPEUTICS, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20150297736-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | 3I, LP | 2015-10-22 | — | — | US | disclosed |
| US-9040032-B2 | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20150031635-A1 | Pharmaceutical Compositions with Attenuated Release of Phenolic Opioids | 3I, LP | 2015-01-29 | — | — | US | disclosed |
| US-8802681-B2 | Pharmaceutical compositions with attenuated release of phenolic opioids | SIGNATURE THERAPEUTICS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130210701-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210700-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130090379-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Tapentadol Prodrug | SIGNATURE THERAPEUTICS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| EP-2560490-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | Signature Therapeutics, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2560489-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | Signature Therapeutics, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20110281886-A1 | Pharmaceutical Compositions with Attenuated Release of Phenolic Opioids | 3I, LP | 2011-11-17 | — | — | US | disclosed |
| WO-2011133150-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133149-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133151-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PHENOL-MODIFIED OPIOID PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20110262360-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031635-A1 | Pharmaceutical Compositions with Attenuated Release of Phenolic Opioids | COMT, OPRM1, OPRK1 | MAPT 1446/4885ANPEP 59/4885DPP8 115/4885 |
| US-20130210701-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | ACHE, OPRM1, DNPEP | MAPT 1589/4885ANPEP 31/4885DPP8 151/4885 |
| US-20110262360-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof | COMT, OPRM1, DNPEP | MAPT 1921/4885ANPEP 49/4885DPP8 136/4885 |
| US-20130090379-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Tapentadol Prodrug | CYP2C9, ACHE, COMT | MAPT 1902/4885ANPEP 45/4885DPP8 177/4885 |
| US-20110281886-A1 | Pharmaceutical Compositions with Attenuated Release of Phenolic Opioids | COMT, OPRM1, OPRK1 | MAPT 1446/4885ANPEP 59/4885DPP8 115/4885 |
| US-20130210700-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof | COMT, OPRM1, DNPEP | MAPT 1921/4885ANPEP 49/4885DPP8 136/4885 |
| US-20150297736-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | ACHE, OPRM1, DNPEP | MAPT 1589/4885ANPEP 31/4885DPP8 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.